Dofetilide Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Apr 4, 2022.
Dofetilide is also known as: Tikosyn
Dofetilide Pregnancy Warnings
Animal studies have revealed adversely affected in utero growth and survival. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Dofetilide Breastfeeding Warnings
Breastfeeding is not recommended during use of this drug.
Excreted into human milk: Unknown
Excreted into animal milk: Unknown
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals (2001):
References for breastfeeding information
- "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals (2001):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
